Citigroup Maintains Buy on Abbott Laboratories, Raises Price Target to $127
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Joanna Wiensch maintains a Buy rating on Abbott Laboratories and raises the price target from $119 to $127.
August 22, 2024 | 3:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup analyst Joanna Wiensch has reaffirmed a Buy rating on Abbott Laboratories and increased the price target from $119 to $127, indicating a positive outlook for the stock.
The increase in price target from $119 to $127 by Citigroup suggests a positive outlook for Abbott Laboratories. The reaffirmation of the Buy rating indicates confidence in the company's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100